Healthcare Innovation April 30, 2021
David Raths

“The data available through MyCode provides us with a unique opportunity to investigate the genetic risk of cancer in a large regional population,” says Geisinger’s David J. Carey, Ph.D.

Researchers at the Geisinger health system in Pennsylvania are studying the role of genetic variation in cancer with a $3.6 million grant from the National Cancer Institute.

Geisinger researchers and the NCI’s Division of Cancer Epidemiology and Genetics (DCEG) will analyze genetic data from Geisinger’s MyCode Community Health Initiative, a precision medicine project with more than 276,000 consented participants.

The investigative team will use a “genome-first” approach, analyzing data from MyCode participants to identify specific gene variants and then linking that information to the participants’ electronic health records. This approach...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, EMR / EHR, Health IT, Health System / Hospital, Pharma / Biotech, Provider, Survey / Study, Technology, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article